Heart failure not responsive to standard immunosuppressive therapy is successfully treated with high dose intravenous immunoglobulin therapy in a patient with Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Int Immunopharmacol. 2017 Apr:45:13-15. doi: 10.1016/j.intimp.2017.01.025. Epub 2017 Jan 31.

Abstract

Glucocorticoids and immunosuppressive drugs represent the first-line treatment of eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss syndrome), even though the combined therapy is not successful in achieving the disease remission in some patients with neurological or cardiac involvement. We describe a case of an EGPA male patient with impaired left ventricular function not responsive to glucocorticoid and immunosuppressive therapy. We observed that high-dose (2g/kg/4weeks) intravenous immunoglobulin (IVIG) therapy significantly improved cardiac function, which was deteriorated after reducing IVIG dose at 0.5g/kg/4weeks, and was restored increasing again IVIG dose to 2g/kg/4weeks. The finding highlights the relevance of IVIG as treatment of choice in EGPA patients with cardiac involvement not responsive to the standard glucocorticoid and immunosuppressive therapy. Moreover, at a follow-up of 24months, the continuance of high dose IVIG therapy was required to maintain a sustained remission of the heart failure.

Keywords: Cardiac involvement; Churg-Strauss syndrome; EGPA; Heart failure; IVIG.

Publication types

  • Case Reports

MeSH terms

  • Churg-Strauss Syndrome / immunology
  • Churg-Strauss Syndrome / therapy*
  • Drug Resistance
  • Glucocorticoids / therapeutic use
  • Granulomatosis with Polyangiitis / immunology
  • Granulomatosis with Polyangiitis / therapy*
  • Heart / drug effects
  • Heart / physiology*
  • Heart Failure / immunology
  • Heart Failure / therapy*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Middle Aged
  • Recovery of Function
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents